1
项与 Epigallocatechin Gallate/Sofosbuvir/Daclatasvir/Ribavirin 相关的临床试验A Phase 3 Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus (EPGCG, Sofosbuvir , Daclatasvir & Ribavirin) Versus Sofosbuvir + Daclatasvir + Ribavirin (Part A) and a Single Dose of Dactavira (EPGCG, Sofosbuvir & Daclatasvir) Versus Sofosbuvir + Daclatasvir (Part B) in Egyptian Adults With Chronic Genotype 4 HCV Infection
A phase 3 Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of the combined single dose of Dactavira Plus (EPGCG, Sofosbuvir , Daclatasvir & Ribavirin) versus Sofosbuvir + Daclatasvir + Ribavirin (Part A) and a single dose of Dactavira (EPGCG, Sofosbuvir & Daclatasvir) versus Sofosbuvir + Daclatasvir (Part B) in Egyptian Adults with Chronic Genotype 4 HCV Infection.
100 项与 Epigallocatechin Gallate/Sofosbuvir/Daclatasvir/Ribavirin 相关的临床结果
100 项与 Epigallocatechin Gallate/Sofosbuvir/Daclatasvir/Ribavirin 相关的转化医学
100 项与 Epigallocatechin Gallate/Sofosbuvir/Daclatasvir/Ribavirin 相关的专利(医药)
100 项与 Epigallocatechin Gallate/Sofosbuvir/Daclatasvir/Ribavirin 相关的药物交易